{"filing":{"accession_number":"0001493152-26-035185","cik":"0001595353","ticker":"GLMD","company_name":"Galmed Pharmaceuticals Ltd.","form":"6-K","filing_date":"2026-07-29","report_date":"2026-07-29","primary_document":"form6-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1595353/000149315226035185/form6-k.htm"},"events":[{"id":21585,"run_id":19472,"accession_number":"0001493152-26-035185","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Galmed terminated a license agreement with Yissum dated June 28, 2021, effective July 31, 2026, resulting in reversion of all licensed technology rights and cessation of patent funding obligations. The company stated the termination was part of efforts to \"consolidate operations, reduce costs and focus resources on the commercialization of Colospan and continued development of Aramchol.\" This is a material operational/strategic decision affecting the company's technology portfolio and R\u0026D focus, but does not fit the specific categories of M\u0026A activity, workforce reduction, or material litigation.","company_name":"Galmed Pharmaceuticals Ltd.","ticker":"GLMD","filing_date":"2026-07-29","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":21258,"accession_number":"0001493152-26-035185","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Galmed terminated a license agreement with Yissum dated June 28, 2021, effective July 31, 2026, resulting in reversion of all licensed technology rights and cessation of patent funding obligations. The company stated the termination was part of efforts to \"consolidate operations, reduce costs and focus resources on the commercialization of Colospan and continued development of Aramchol.\" This is a material operational/strategic decision affecting the company's technology portfolio and R\u0026D focus, but does not fit the specific categories of M\u0026A activity, workforce reduction, or material litigation.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-29T20:07:57.936238+00:00","company_name":"Galmed Pharmaceuticals Ltd.","ticker":"GLMD","filing_date":"2026-07-29"}]}